Pelabresib Plus Ruxolitinib Improves Signs of Underlying Myelofibrosis Pathobiology and Provides Clinical Benefit Over JAK Inhibitor Monotherapy By Ogkologos - March 25, 2025 800 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MANIFEST-2 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Molecular Determinantion of Outcomes in a Study with Pembrolizumab for Advanced... August 25, 2021 Moving Beyond BMI: Low Muscle Mass May Affect Cancer Survival April 30, 2018 FDA Extends Approval of Pembrolizumab for Classical Hodgkin Lymphoma October 20, 2020 Should People With Cancer Be Tested for Hepatitis B? July 27, 2020 Load more HOT NEWS Trial Results Highlight Changing Lung Cancer Treatment Landscape Adding Pembrolizumab to Docetaxel Does Not Significantly Improve Outcomes in Patients... Additional 5 Years of AI Treatment Reduces Distant Recurrence Rates Among... Neoadjuvant ICI Without Chemotherapy Demonstrates Potential Efficacy in Patients with Early-Stage...
